|

adjuvant immunotherapy Clinical Trials

3 actively recruiting trials

▲ +1 trial since August 2026

Pipeline

Phase 3: 2

Top Sponsors

  • Sun Yat-sen University1
  • RenJi Hospital1
  • Fudan University1

Indications

  • Cancer3
  • Resectable Stage II-IIIa NSCLC1
  • Muscle Invasive Upper Tract Urothelial Carcinoma1
  • De-escaltion Therapy1
  • Nasopharyngeal Carcinoma1

Other3 trials

Circulating and Urine Tumor DNA Dynamics Predict Minimal Residual Disease and Recurrence Risk in Locally Advanced Upper Tract Urothelial Carcinoma
Comparison of Perioperative Immunotherapy, Adjuvant Immunotherapy or Neoadjuvant Immunotherapy for Resectable Stage II-IIIA NSCLC
Phase 3
Reduced-target Resection After Induction Chemotherapy in Resectable Recurrent Nasopharyngeal Carcinoma
Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.